Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2025-11-13 00:00:00 ET · period of report 2025-11-11 · accession 0001193125-25-280792 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-13 | 2025-11-13 | VERA | Young Joseph R | SVP, Fin, CHIEF ACCT OFFCR | M - OptEx | $3.94 | +10.0K | 57.8K | +21% | +$39.4K |
| D | 2025-11-13 | 2025-11-11 | VERA | Young Joseph R | SVP, Fin, CHIEF ACCT OFFCR | S - Sale+OE | $29.06 | -15.0K | 47.8K | -24% | -$435.9K |
| D | 2025-11-13 | 2025-11-13 | VERA | Young Joseph R | SVP, Fin, CHIEF ACCT OFFCR | M - OptEx | $0.00 | -10.0K | 48.6K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-11-13 | M | A | 10,000 | $3.94 | 57,839 | D | — | — | |
| 2 | Common | Class A Common Stock | 2025-11-11 | S | D | 15,000 | $29.06 | 47,839 | D | — | — | (F1) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.17, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F2) Includes 893 ordinary shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan. |
| 3 | Derivative | Stock Option (right to buy) | 2025-11-13 | M | D | 10,000 | $0.00 | 48,589 | D | $3.94 · — to 2031-04-13 | 10,000 Class A Common Stock | (F3) 1/4 of the shares subject to the option vest on March 9, 2022, and 1/48 of the shares vest monthly thereafter. |